The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... Module 2 included 4 patients with non-small cell lung cancer (NSCLC) or pleural mesothelioma who had disease progression ...
INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback